NDATOPICALAEROSOL, FOAM
Approved
Oct 2015
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
8
Data completeness
7/8 — Comprehensive
ENSTILAR (calcipotriene and betamethasone dipropionate) by Leo Pharma is d3 analog and betamethasone dipropionate as a synthetic corticosteroid. Approved for plaque psoriasis. First approved in 2015.
Drug data last refreshed Yesterday · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ENSTILAR is a fixed-dose combination topical foam containing calcipotriene (a vitamin D3 analog) and betamethasone dipropionate (a synthetic corticosteroid) approved by the FDA in October 2015 for the treatment of plaque psoriasis. The product combines two complementary mechanisms: the D3 analog works through vitamin D receptor pathways while the corticosteroid provides anti-inflammatory effects, though the exact mechanisms in psoriasis treatment remain incompletely understood. ENSTILAR represents a convenient foam formulation approach to combination topical therapy and is positioned as a branded treatment option in the moderate psoriasis market.
$0.0BPart D
5.6 years to LOEMechanism of Action
D3 analog and betamethasone dipropionate as a synthetic corticosteroid. However, while their pharmacologic and clinical effects are known, the exact mechanisms of their actions in the treatment of plaque psoriasis are unknown.
Indications (1)
Clinical Trials (8)
A Study Evaluating the Efficacy and Tolerability of Enstilar Foam in Patients With Nail Psoriasis
Started Nov 2021
6 enrolled
Nail Psoriasis
Assessing the Efficacy of Image-guided Laser-assisted Enstilar® Delivery for Treatment of Psoriatic Nails
Started Oct 2020
11 enrolled
Nail Psoriasis
Taltz in Combination With Enstilar for Psoriasis
Started Apr 2020
25 enrolled
Psoriasis
Observational Study in Patients With Nail Psoriasis Treated With Enstilar® to Assess the Severity Change and the Quality of Life
Started Mar 2019
10 enrolled
Nail Psoriasis
Enstilar in Combination With Enbrel or Humira for Plaque Psoriasis
Started Jan 2019
30 enrolled
Psoriasis
Worked on ENSTILAR at Leo Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.